US2019307685A1PendingUtilityA1

Nonsteroidal immunomodulating kit and composition and uses thereof

Assignee: FOAMIX PHARMACEUTICALS LTDPriority: Oct 25, 2002Filed: Dec 11, 2018Published: Oct 10, 2019
Est. expiryOct 25, 2022(expired)· nominal 20-yr term from priority
A61K 9/122A61K 31/07A61K 8/671A61K 31/203A61K 9/10A61K 8/046A61Q 19/00A61K 9/0014
68
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A composition and therapeutic kit including an aerosol packaging assembly including a container accommodating a pressurized product and an outlet capable of releasing a foamable composition, including a nonsteroidal immunomodulating agent as a foam. The pressurized product includes a foamable composition including: a) a container accommodating a pressurized product; and b) an outlet capable of releasing the pressurized product as a foam; wherein the pressurized product comprises a foamable composition including: i. a nonsteroidal immunomodulating agent; ii. at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight; iii. a surface-active agent; iv. about 0.1% to about 5% by weight of a therapeutically active foam adjuvant, selected from the group consisting of a fatty alcohol, a fatty acid, a hydroxyl fatty acid; and mixtures thereof; v. about 0.01% to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent; vi. water; and vii. liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 - 32 . (canceled) 
     
     
         33 . A method of treating an inflammatory disorder of skin, a body cavity, or a mucosal surface, comprising administering topically to a subject having the disorder a foam composition,
 wherein the foam composition comprises:   a) a therapeutically effective amount of a nonsteroidal immunomodulating agent;   b) at least one organic carrier selected from a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight;   c) a surface-active agent at a concentration of about 0.1% to about 5% by weight;   d) a polymeric additive, at a concentration of about 0.01% to about 5% by weight, selected from a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent;   e) a foam adjuvant at a concentration of about 0.1% to about 5% by weight; and   f) water.

Join the waitlist — get patent alerts

Track US2019307685A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.